News

The new EU Medical Device Regulation (MDR) 2017/745, which will come into full effect in May 2021, has a major impact on medical device manufacturers worldwide. Implementation of the new regulations has manufacturers facing challenges due to the stricter rules, limited resources, and lack of clear EU guidance. Therefore, we are especially proud to announce that Thirona successfully implemented the requirements and we are now certified against the new MDR.

Thirona has obtained an exclusive license on a patent in relation to Cystic Fibrosis (CF),  a rare genetic condition that creates lung abnormalities from a very early age. The patent allows us to develop an AI algorithm that will analyse CT scans to identify even the smallest abnormalities in the lungs, especially early on, ensuring that the right treatment can follow.

Public-private consortium P4O2 (Precision Medicine for more Oxygen) investigates risk factors for developing lung damage and chronic complaints after COVID-19  30 September 2020 Many patients who have had COVID-19 continue to have health complaints for [...]

MedicalVR has integrated Thirona's chest CT analysis software in their virtual reality application PulmoVR. It provides surgeons with an interactive 3D visualization of the lungs for pre-operative planning. Patient-specific anatomical labels and segmentation are added by [...]

Thirona Teams Up with Smart Reporting to Further Improve COVID-19 Detection

Thirona is present at the online congress of the European Society of Radiology (ECR) which is held from July 15-19. You can find us in stand 1547 at Expo Hall X6

In this first study the performance of an AI system for COVID19 detection on chest X-rays was compared to human expert readers. The results show that CAD4COVID-XRay can identify characteristics of COVID-19 on chest radiographs with performance comparable to six experienced radiologists.

We are honoured that CAD4COVID has been nominated for the Top 10 innovation at COVID-19 Innovation Challenge 2020 organized by the UNECA.

Our RetCAD solution is cleared for clinical use in New Zealand. We look forward to working with our users in New Zealand on the analysis of their retinal images.

Today, June 10th 2020, our Notified Body has granted CE certifications for both our CAD4COVID-CT and CAD4COVID-XRay solutions. Both have been granted Class II CE certifications, meaning they can officially be used as tools to aid in the interpretation of imaging COVID-19. The CE (0344) approval will help to further support the roll-out of both solutions, which will continue to be available free-of-charge to support healthcare facilities globally to face the pandemic.

Our chest CT analysis product LungQ is now cleared for clinical use in South Korea. We look forward to working with our South Korean users on quantitative analysis of their chest CT scans.

Today, we are proud to launch CAD4COVID-CT, our artificial intelligence software for the analysis of COVID-19 on CT scans. Three weeks ago, we already launched our X-ray based solution for COVID-19 (CAD4COVID-Xray) in collaboration with Delft Imaging, which has since been made accessible to healthcare facilities in twelve countries. Click to read more and visit https://thirona.eu/cad4covid/ or email info@thirona.eu.

Thirona is specialized in tuberculosis (TB) screening and with its proven CAD4TB solution has screened over 6 million people in 40 countries. We optimised CAD4TB to triage COVID-19 suspects and are launching this solution free-of-charge.

We are present at the Saudi Opthalmology conference held from 12-14 March in the Hilton Ryadh Hotel. Come by to meet us and learn more about our Retina solution RetCAD.